Molecular mechanisms coordinating membrane trafficking and ion transport in health and disease

Over the last few decades, studies in my lab have made substantial contributions to the understanding of cellular trafficking pathways at the morpho-functional level. This has provided us with a solid temporal and topographical framework for the study of the molecular machineries implicated in membrane sorting and trafficking processes. Therefore, our goal is to identify and characterize new molecular pathways operating in sorting and trafficking events under pathological conditions with a specific focus on genetic disorders and cancer.

Currently, the lab’s researchers are focused on the role of membrane trafficking in copper homeostasis and on the interplay between this process and ion transport, quality control and the cell polarity mechanisms which participate in the maintenance of copper balance in the body. In recent years, it has become clear that several genetic disorders of copper metabolism are caused by mutations that affect either the expression of copper transporters or their ability to reach the specific cellular sites, where they would be expected to execute their functions.
Among these transporters, ATP7A and ATP7B, also known as copper (Cu) ATPases, represent proteins with key roles in regulating copper levels in the body. Mutations do not allow aberrant Cu ATPases to be efficiently expressed or to move properly through the secretory pathway towards the specific sites in which Cu transport is needed, therefore, resulting in either ATP7A-dependent Cu deficiency (Menkes disease) or ATP7B-dependent Cu toxicosis (Wilson disease). Unfortunately, the mechanisms that might be used to compensate the loss of ATP7A/B function remain poorly understood. The aim of our studies is to identify such mechanisms and explore them for normalization of Cu homeostasis and for correction of trafficking of aberrant ATP7A/B variants.

In addition to genetic disorders, recent studies suggest that Cu ATPases play an important role in oncogenesis and resistance of tumors to chemotherapy. As a consequence, tumor-specific suppression of ATP7A/B has emerged as an attractive strategy to counteract tumor growth and metastasis. In this context, our studies of the mechanisms that drive ATP7A/B dysfunction in genetic disorders have opened a new research line that is focused on how to use these mechanisms to combat cancer.

1. Pharmacoproteomics pinpoints HSP70 interaction for correction of the most frequent Wilson disease-causing mutant of ATP7B.  PNAS, 2020
2. Synthetic Lethality Screening Identifies FDA-Approved Drugs that Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin. Cancers, 2020
3. Activation of autophagy, observed in liver tissues from patients with Wilson disease and from Atp7b-deficient animals, protects hepatocytes from copper-induced apoptosis. Gastroenterology, 2019
4. Identification of p38 MAPK and JNK as new targets for correction of Wilson disease-causing ATP7B mutants. Hepatology, 2016
5. Wilson disease protein ATP7B utilizes lysosomal exocytosis to maintain copper homeostasis. Developmental Cell, 2014

Complete List of Published Work in MyBibliography